Kuehn Law Encourages Investors of Aardvark Therapeutics, Inc. to Contact Law Firm

NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Aardvark Therapeutics, Inc. (NASDAQ: AARD) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Aardvark Therapeutics misrepresented or failed to disclose that: (i) the Company's IPO-related documents filed with the SEC were negligently prepared and as a result contained materially untrue or misleading statements; (ii) ARD-101, the Company's lead product candidate, was less safe than Aarkvark had led investors to believe; and (iii) accordingly, ARD-101's clinical, regulatory, and commercial prospects were overstated.

If you currently own AARD and purchased prior to March 1, 2025 please contact Sophia Anne Silayan, by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814

SOURCE Kuehn Law, PLLC